[BIO 2026] Everfront Biotech to Present at BIO International Convention 2026
Date: June 12, 2026
During its company presentation at BIO 2026, Everfront Biotech will showcase its core technology for the precision treatment of brain tumors—the biodegradable intracranial implant system (Cerebraca® Wafer / EF-001). We cordially invite you to attend and join us in exploring this milestone of translating science into real-world impact. (This image is a conceptual illustration; some visual effects are AI-assisted.)
Everfront Biotech Holding Company is pleased to announce its participation as a speaker at the BIO International Convention 2026, taking place in San Diego, California, from June 22–25, 2026. As the world’s largest biotechnology industry event, the convention convenes over 20,000 biotech leaders, investors, and innovators from across the global life sciences ecosystem.
At BIO 2026, Everfront Biotech will share key insights on Cerebraca® Wafer (EF-001), our late-clinical CNS oncology asset entering a pivotal Phase IIb/III study for recurrent glioblastoma. During the presentation, the company will also discuss strategic partnership opportunities and upcoming clinical development milestones.
We look forward to connecting with partners, investors, and innovators who share our commitment to turning science into real-world impact.
Schedule a Partnering Meeting
To arrange a one-on-one meeting with our team at the convention, please contact:
Jui-Hao Lee
Strategic Partnership | Everfront Biotech Holding Company
📧 Email: juihaolee@efbiotech.com
🌐 Website: www.efbiotech.com
Product Highlights of Cerebraca® Wafer:
Cerebraca® Wafer is a revolutionary implantable drug designed for the localized treatment of malignant brain tumors. Developed using multiple patented innovations, the product aims to solve critical challenges in brain cancer therapy—such as chemoresistance, high cancer stem cell content, and tumor recurrence.
Cerebraca® Wafer works by targeting receptor tyrosine kinase (RTK) signaling networks, modulating tumor resistance, and counteracting PD-L1-mediated immune evasion, a common barrier to effective treatment. In Phase I/IIa trials, no drug-related adverse effects were reported. Recurrent GBM patients showed a median overall survival of 15.7 months, with RTK-high subgroups reaching up to 26.2 months—a significant improvement over the current standard of care (6–9 months).
Everfront Biotech is actively seeking strategic partnerships and licensing opportunities to co-develop this promising therapy and extend its benefits to more patients worldwide.
Introduction to Everfront Biotech Inc.:
Everfront Biotech Inc. was founded in 2010, with a focus on research and development of new drugs, specifically the screening and further development of potential small molecules for clinical study. The company’s team is responsible for all aspects of product development, from front-end potential product development to pre-clinical research, chemistry manufacturing and controls (CMC), clinical trial submissions, and clinical trial planning and execution. To date, the Everfront Biotech team has successfully applied three clinical trials: Cerebraca® Wafer (for malignant brain tumors), HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer), which have been approved for IND applications in both the United States and Taiwan.
Everfront Biotech’s new drug development is in line with national policies, and the Cerebraca® Wafer and HK-001 products were granted the certifications of biotech and new drug in 2016. The company has received the government subsidies in three science and technology projects as of 2022 from the Ministry of Economic Affairs.
